Literature DB >> 20006486

Targeting the PI3K signaling pathway in cancer.

Kwok-Kin Wong1, Jeffrey A Engelman, Lewis C Cantley.   

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20006486      PMCID： PMC2822054          DOI： 10.1016/j.gde.2009.11.002

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN： 0959-437X            Impact factor:   5.578


  32 in total

1.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

2.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Authors:  Olga K Mirzoeva; Debopriya Das; Laura M Heiser; Sanchita Bhattacharya; Doris Siwak; Rina Gendelman; Nora Bayani; Nicholas J Wang; Richard M Neve; Yinghui Guan; Zhi Hu; Zachary Knight; Heidi S Feiler; Philippe Gascard; Bahram Parvin; Paul T Spellman; Kevan M Shokat; Andrew J Wyrobek; Mina J Bissell; Frank McCormick; Wen-Lin Kuo; Gordon B Mills; Joe W Gray; W Michael Korn
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

3.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

Authors:  Marta Guix; Anthony C Faber; Shizhen Emily Wang; Maria Graciela Olivares; Youngchul Song; Sherman Qu; Cammie Rinehart; Brenda Seidel; Douglas Yee; Carlos L Arteaga; Jeffrey A Engelman
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

4.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Authors:  Violeta Serra; Ben Markman; Maurizio Scaltriti; Pieter J A Eichhorn; Vanesa Valero; Marta Guzman; Maria Luisa Botero; Elisabeth Llonch; Francesco Atzori; Serena Di Cosimo; Michel Maira; Carlos Garcia-Echeverria; Josep Lluis Parra; Joaquin Arribas; José Baselga
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 5.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

6.  Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors:  Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

7.  BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Authors:  Daniel B Costa; Balázs Halmos; Amit Kumar; Susan T Schumer; Mark S Huberman; Titus J Boggon; Daniel G Tenen; Susumu Kobayashi
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069

8.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

9.  Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.

Authors:  Yixuan Gong; Romel Somwar; Katerina Politi; Marissa Balak; Juliann Chmielecki; Xuejun Jiang; William Pao
Journal:  PLoS Med       Date:  2007-10-09       Impact factor: 11.069

10.  Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.

Authors:  Mark S Cragg; Junya Kuroda; Hamsa Puthalakath; David C S Huang; Andreas Strasser
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069
View more
  239 in total

Review 1.  Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation.

Authors:  Liqin Du; Alexander Pertsemlidis
Journal:  J Mol Cell Biol       Date:  2011-01-28       Impact factor: 6.216

2.  Activation of PI3K signaling in Merkel cell carcinoma.

Authors:  Valentina Nardi; Youngchul Song; Juan A Santamaria-Barria; Arjola K Cosper; Quynh Lam; Anthony C Faber; Genevieve M Boland; Beow Y Yeap; Kristin Bergethon; Vanessa L Scialabba; Hensin Tsao; Jeffrey Settleman; David P Ryan; Darrell R Borger; Atul K Bhan; Mai P Hoang; Anthony J Iafrate; James C Cusack; Jeffrey A Engelman; Dora Dias-Santagata
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

3.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

4.  Driver mutations: a roadmap for getting close and personal in pancreatic cancer.

Authors:  Murray Korc
Journal:  Cancer Biol Ther       Date:  2010-09-24       Impact factor: 4.742

Review 5.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 6.  Lin28 and let-7 in cell metabolism and cancer.

Authors:  Liem H Nguyen; Hao Zhu
Journal:  Transl Pediatr       Date:  2015-01

7.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Authors:  Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

8.  Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.

Authors:  Mi-Sung Kim; Jong-Eun Kim; Do Young Lim; Zunnan Huang; Hanyong Chen; Alyssa Langfald; Ronald A Lubet; Clinton J Grubbs; Zigang Dong; Ann M Bode
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-10

9.  Antitumor activity of the Ailanthus altissima bark phytochemical ailanthone against breast cancer MCF-7 cells.

Authors:  Ruxing Wang; Yanjie Lu; Hong Li; Lixin Sun; Ning Yang; Mingzhen Zhao; Manli Zhang; Qingwen Shi
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

Review 10.  Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions.

Authors:  Nikki A Ford; Kaylyn L Devlin; Laura M Lashinger; Stephen D Hursting
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-04       Impact factor: 2.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.